ProPhase Labs, Inc. (NASDAQ:PRPH) Sees Large Decline in Short Interest

ProPhase Labs, Inc. (NASDAQ:PRPH) saw a large decline in short interest during the month of February. As of February 28th, there was short interest totalling 1,660,000 shares, a decline of 62.4% from the February 13th total of 4,420,000 shares. Approximately 8.8% of the shares of the stock are short sold. Based on an average daily trading volume, of 8,860,000 shares, the short-interest ratio is presently 0.2 days.

ProPhase Labs Price Performance

NASDAQ PRPH traded down $0.03 during mid-day trading on Thursday, hitting $0.43. The stock had a trading volume of 786,944 shares, compared to its average volume of 11,928,803. The firm’s 50 day moving average is $0.47 and its 200 day moving average is $1.26. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.47 and a quick ratio of 1.33. The stock has a market capitalization of $10.16 million, a price-to-earnings ratio of -0.34 and a beta of -0.53. ProPhase Labs has a twelve month low of $0.22 and a twelve month high of $7.48.

Hedge Funds Weigh In On ProPhase Labs

Several hedge funds and other institutional investors have recently modified their holdings of PRPH. SVB Wealth LLC purchased a new stake in ProPhase Labs during the 4th quarter valued at about $36,000. Squarepoint Ops LLC acquired a new stake in shares of ProPhase Labs in the fourth quarter valued at approximately $40,000. Warberg Asset Management LLC purchased a new position in ProPhase Labs during the fourth quarter worth approximately $77,000. Perritt Capital Management Inc boosted its stake in ProPhase Labs by 129.1% during the fourth quarter. Perritt Capital Management Inc now owns 190,000 shares of the company’s stock worth $144,000 after buying an additional 107,068 shares during the last quarter. Finally, Geode Capital Management LLC boosted its stake in ProPhase Labs by 26.6% during the fourth quarter. Geode Capital Management LLC now owns 203,528 shares of the company’s stock worth $154,000 after buying an additional 42,793 shares during the last quarter. 9.45% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, StockNews.com assumed coverage on ProPhase Labs in a report on Tuesday, February 25th. They set a “sell” rating for the company.

About ProPhase Labs

ProPhase Labs, Inc develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.